Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Total Non-Current Liabilities (2016 - 2020)

International Stem Cell (ISCO) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $5.4 million as the latest value for Q3 2020.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $5.4 million in Q3 2020 year-over-year; TTM through Sep 2020 was $5.4 million, a N/A change, with the full-year FY2019 number at $5.0 million, up 42.32% from a year prior.
  • Total Non-Current Liabilities was $5.4 million for Q3 2020 at International Stem Cell, down from $5.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $5.8 million in Q2 2020 to a low of $1.6 million in Q4 2016.
  • A 5-year average of $3.6 million and a median of $3.7 million in 2017 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: tumbled 70.67% in 2016, then surged 163.68% in 2017.
  • International Stem Cell's Total Non-Current Liabilities stood at $1.6 million in 2016, then rose by 8.42% to $1.7 million in 2017, then skyrocketed by 108.3% to $3.5 million in 2018, then skyrocketed by 42.32% to $5.0 million in 2019, then grew by 7.72% to $5.4 million in 2020.
  • Per Business Quant, the three most recent readings for ISCO's Total Non-Current Liabilities are $5.4 million (Q3 2020), $5.8 million (Q2 2020), and $5.3 million (Q1 2020).